Transcatheter Mitral Valve Implantation (TMVI) Using Edwards SAPIEN 3 Prostheses in Patients at Very High or Prohibitive Surgical Risk: A Single-Center Experience
Table 1
Patient demographics and comorbidities.
Patients treated (n = 7)
Female gender
86%
Age (years, mean, SD)
77 ± 8.1
Time since last mitral valve operation (month, mean, SD, n = 4)
161 ± 24
Number of thoracotomies per patient (median, IQR)
1 (1 to 1)
NYHA functional class prior to procedure
NYHA class IV
57% (4/7)
NYHA class III
43% (3/7)
NYHA class II
0% (0/7)
NYHA class I
0% (0/7)
Leading mitral valve dysfunction (native mitral valve, annuloplasty ring, or prosthesis)